Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zafirlukast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| zafirlukast | EXPERIMENTAL | Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited |
| Accolate | ACTIVE_COMPARATOR | ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals |
| Name | Type | Description |
|---|---|---|
| Zafirlukast | DRUG | Zafirlukast tablets 20 mg |
Inclusion Criteria: 1. The subjects should be healthy human between 18 and 45 years. 2. The subjects should be screened within 21 days prior to the administration of first dose of the study drug. 3. The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter. 4. The subjects...
Zafirlukast is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is being studied in a Phase 1 clinical trial. The specific medical condition it is intended to treat has not been disclosed.
Zafirlukast targets CYSLTR1, a receptor protein. It acts as an antagonist at this target, meaning it blocks the receptor's activity. This mechanism is characteristic of small molecule drugs in its class.
Zafirlukast is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company whose shares trade under the ticker symbol RDY. The company is responsible for its clinical development.
Zafirlukast is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The only recorded trial is a completed Phase 1 study.
Zafirlukast has been studied in one clinical trial: NCT01283061, titled "Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition." This Phase 1 trial was completed and enrolled 44 healthy volunteers in India.